You’ll be ‘in trouble’ if you’re not up to speed on COVID vaccines and boosters – here are 3 stocks that can help

You'll be 'in trouble' if you're not up to speed on COVID vaccines and boosters - here are 3 stocks that can help
Written by boustamohamed31

Dr. Fauci: 'You'll get yourself in trouble' if you don't keep up with COVID vaccines and boosters - here are 3 stocks that can help

Dr. Fauci: ‘You’ll get yourself in trouble’ if you don’t keep up with COVID vaccines and boosters – here are 3 stocks that can help

With the summer travel season in full swing, the COVID-19 pandemic may seem like a thing of the past.

But if you don’t keep up with your shots and boosters, the consequences can be dire, according to President Biden’s chief medical adviser, Dr. Anthony Fauci.

“If they don’t get vaccinated or boosted, they’re going to get into trouble,” said Dr. Fauci told KNX News 97.1 — a Los Angeles radio station — earlier this week.

He points out that America’s vaccine and booster rates are “pretty disheartening.”

According to the Kaiser Family Foundation, 228 million Americans (or 70% of the US population) were not up to date on their COVID-19 vaccines as of July 20, 2022. Staying “up to date” on vaccines means having received the primary series and at least one booster dose.

It is difficult to say whether Dr. Fauci’s warning will lead to more Americans getting COVID-19 vaccines and booster shots. But it does give investors reason to check out the companies that make these vaccines.

Do not miss

Modern (MRNA)

Currently, the most dominant strain of COVID in the US is Omicron’s BA.5 subvariant. And Moderna can help the country fight it.

Earlier this week, the company’s CEO Stefan Bansel told Yahoo Finance that they are “working really hard” to prepare a variant-specific booster this fall.

“We are already making the BA.4/5 vaccine as we speak,” he says. “We’ll give more data as we get closer to it, but we know how important it is.” And know that every day counts.”

In the second quarter, Moderna generated $4.7 billion in total revenue, up from $4.4 billion earned a year ago. Management attributed the top-line increase to higher product sales of the company’s COVID-19 vaccine.

But Moderna’s stock is not immune to market sell-offs this year. They have fallen by about 20% in 2022.

Piper Sandler analyst Edward Tenthoff has an “overweight” rating on Moderna and a $214 price target — roughly 14% above today’s share price.

BioNTech (BNTX)

BioNTech is another big name in the COVID vaccine business.

According to Statista, more than 355,396,322 doses of Pfizer-BioNTech’s COVID-19 vaccine had been administered in the US as of July 20 – more than vaccines made by any other manufacturer.

On June 25, Pfizer and BioNTech announced that their Omicron-adapted vaccine candidates showed high immune responses against Omicron.

There is also hope for tackling new sub-variants.

“Preliminary laboratory studies show that both Omicron-adapted candidates neutralize Omicron BA.4 and BA.5, albeit to a lesser extent than for BA.1,” the companies said, while continuing to “collect additional data from the Omicron BA.4 /BA.5 study.”

BioNTech will report second-quarter earnings on Monday, August. 8 before the bell.

Management previously said it expected BioNTech’s COVID-19 vaccine revenue to reach between €13 billion and €17 billion for the full year 2022.

Last month, SVB Securities analyst Dayna Graybosch upgraded BioNTech from “market perform” to “outperform.” Her $233 price target on the stock suggests a potential upside of 28%.

Novavax (NVAX)

When it comes to COVID vaccine stocks, Novavax is a new name worth considering.

Last month, the US Food and Drug Administration granted emergency use authorization for the adjuvanted Novavax COVID-19 vaccine (NVX-CoV2373). In the critical phase 3 clinical trial, the two-dose vaccine was 90.4% effective in preventing mild, moderate or severe COVID-19.

“This authorization reflects the strength of the efficacy and safety data for our COVID-19 vaccine and underscores the critical need to offer another vaccine option to the US population as the pandemic continues,” said Novavax President and CEO Stanley S. Erk in a press release.

Novavax shares have taken a hit, however, and are down a staggering 57% year to date.

B. Riley Securities analyst Mayank Mamtani sees a recovery on the horizon. He has a Buy rating on Novavax and a $171 price target.

Given that Novavax is currently trading at around $60 per share, Mamtani’s price target suggests potential growth from 185%

What to read next

  • register for our MoneyWise Investing Newsletter to receive a steady stream of actionable ideas of the leading firms on Wall Street.

  • The US is just days away from an ‘absolute explosion’ of inflation — here it is 3 shockproof sectors to protect your portfolio

  • “There’s always a bull market somewhere”: Jim Cramer’s famous words suggest that you can make money no matter what. They are here 2 strong headwinds to take advantage of today

This article provides information only and should not be construed as advice. Provided without any warranty.

About the author


Leave a Comment